No abstract available.
Gastrectomy* ; Stomach Neoplasms* ; Stomach*

No abstract available.
Breast* ; Female ; Humans

No abstract available.
Colorectal Neoplasms*

No abstract available.
Humans ; Male* ; Thyroid Diseases* ; Thyroid Gland*

Background: Korea is no longer safe from the risk of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL); the first reported case was a Korean woman in her 40s who had a 7-year-history of receiving an implant-based augmentation mammaplasty using a textured implant. We conducted this study to discuss the emerging crisis of stakeholders in implant-based augmentation mammaplasty and to propose a multi-disciplinary approach to early detection of its complications. Methods: We analyzed medical examination data that was collected from patients who visited us between August 12 and September 27, 2019. We evaluated a total of 114 women (n = 114) in the current study. They were evaluated for whether they were in healthy condition. Moreover, their baseline characteristics were also examined; these included age, gender, height (cm), weight (kg), duration since surgery (years), possession of a breast implant card, the site of surgical incision, side of symptoms and reasons for outpatient visit. Furthermore, the patients were also evaluated for their subjective awareness of the manufacturer, surface and shape of the breast implant. Potential complications include malrotation, folding, seroma, capsule thickening, upside-down rotation, rupture, capsule mass and breast mass. Results: A majority of the patients had a past history of receiving textured implants. The corresponding percentage was 78.95% (90/114) and 85.09% (97/114) based on their subjective awareness of a breast implant and sonographic findings, respectively. That is, it was slightly increased with the use of a breast ultrasound. Conclusion Here, we propose the following approaches. First, patient data should be prospectively collected. By tracking outcomes and complications of an implant-based augmentation mammaplasty, both high-quality care and patient safety can be ensured. Second, stakeholders in implant-based augmentation mammaplasty should collaborate with customers and regulatory authorities. Third, surgeons should consider applying imaging modalities for early detection of postoperative complications.

A clinico-pathologic study with an immunohistochemical examination for c-erbB-2 expression in 54 cases of ductal carcinoma in situ and 16 cases of Paget's disease of the breast was performed. c-erbB-2 oncoprotein overexpression was observed in 45% (24/54) and 88% (14/16) of ductal carcinoma in situ and Paget's disease, respectively. The overexpression of c-erbB-2 oncoprotein was significantly correlated with the nuclear grade of tumors and inversely with the status of the estrogen receptor. c-erbB-2 was positive in 4 out of 5 patients with metastasis to axillary lymph nodes and 3 out of 4 patients who died of the disease. Prognostic significance of c-erbB-2 oncoprotein in ductal carcinoma in situ was highly suggested. The expression of c-erbB-2 oncoprotein in Paget's disease was well correlated with coexisting infiltrating or in situ ductal carcinoma. The high positive rate of c-erbB-2 oncoprotein in ductal carcinoma with Paget's disease could be understood with a recent hypothesis that c-erbB-2 oncoprotein is involved in promotion of cell motility and the spread of carcinoma cells.
Neoplasm Metastasis

Neurofibromatosis, first clearly described by von Recklinghausen in 1882, is a dominantly inherited mesodermal and ectodermal dysplasia with a broad spectrum of clinical findings. Most common is the classical neurofibromatosis, which has three major features: (1) multiple neural tumors dispersed anywhere on or in the body; (2) numerous pigmented skin lesions, some of which are "cafe au lait" spots; and (3) pigmented iris hamartomas also called Lisch nodules. Other lesions sometimes seen in patients with von Recklinghausen's disease include congenital malformations of various types, vascular lesions, neurilemoma meningioma and other intracranial neoplasms, pheochromocytoma, medullary carcinoma of thyroid gland, neuroblastoma, ganglioneuroma and Wilms' tumor. Approximately 10% of the patients with neurofibromatosis have the gastrointestinal tract tumors as neurofibroma, ganglioneuroma and leiomyoma. Some of them show evidence of malignancy. Increased activity of the protein "nerve growth factor" in the sera of the patients with disseminated neurofibromatosis has been reported. We would like to report here two cases of von Recklinghausen's neurofibromatosis with involvement of the gastrointestinal tract.
Hamartoma ; Meningioma

Translational initiation is regulated in response to nutrient availabilty and growth stimuli and is coupled with cell cycle progression and cell growth. There is now growing body of evidence which suggests links between translational regulation and the disruption of cell behavior that results in the development and progression of cancer. mRNA translation can be overactivated in breast cancer through eIF4E overexpression or abnormal activation of signal transduction pathways. Among them, rapamycin-sensitive signal transduction pathway (mTOR signaling pathway) is now being studied as a novel target for cancer therapy. In this article, the basic principles of translational control, the alterations encountered in cancer and selected therapy targeting mTOR signaling pathway are reviewed and the preclinical study regarding the determinants of rapamycin sensitivity in breast cancer is presented in order to help elucidate new avenues for breast cancer therapy.
Breast Neoplasms* ; Breast* ; Cell Cycle ; Eukaryotic Initiation Factor-4E ; Protein Biosynthesis ; Signal Transduction ; Sirolimus

Malignant neoplasm is the most common cause of death in Korea since 1988. In terms of incidence, still gastric cancer is the most common cancer in male, but breast cancer became the second most common female cancer followed by thyroid cancer. The reasons why incidence of breast cancer is increasing, (1) Westernized food patterns; high fat and high calorie diet, (2) late marriage with lower birth rate, (3) shorter period of breast feeding, (4) longer exposure to estrogen; early menarche with late menopause, hormone replacement therapy, (5) low physical activity with high body mass index, (6) environmental stress, and etc. Still incidence of breast cancer in Korea is relatively low comparing to those of American and European populations, but it is very rapidly increasing with annual increase rate of about 6%. So Korean breast cancer specialists should try to study breast cancer in terms of basic and also clinical aspect and also educate laymen for etiology, symptoms and signs, early detection method including breast self-examination and prevention.
Birth Rate ; Body Mass Index ; Breast Feeding ; Breast Neoplasms* ; Breast Self-Examination ; Cause of Death ; Diet ; Estrogens ; Female ; Hormone Replacement Therapy ; Humans ; Incidence ; Korea ; Male ; Marriage ; Menarche ; Menopause ; Motor Activity ; Specialization ; Stomach Neoplasms ; Thyroid Neoplasms

Breast cancer is one of the most common malignancies of lethal potential for women in the developed world. Over the past two decades, we have witnessed dramatic advances in the treatment of breast cancer. The golden age of adjuvant systemic therapy for breast cancer began in early 1970s. The early results of the intial clinical trials raised both hopes and innumerable controversies. More importantly, they stimulated many physicians to set up further prospective trials to confirm or rule out the validity of different hypotheses. The initial adjuvant therapy trials used chemotherapy to treat women with lympy node positive cancer. These trials clearly demonstrated a disease-free and overall survival benefit for women receiving combination chemotherapy in the adjuvant setting. These benefits were subsequently extended to women with lymph node negative disease and to women with steroid receptor positive breast cancer. More than 100 randomized clinical trials of breast cancer adjuvant therapy have now been completed. Many of these studies have had more than 20 years of patients follow-up, and firm conclusion can be drawn about the value of treatment in different patients subsets. Although many questions remain to be answered regarding the dose intensity of chemotherapy, the appropriate sequencing of chemotherapy agents, and the use of novel chemotherapy agents such as taxanes, sufficient information is available to conclude that appropriately adminstered adjuvant treatment does improve survival of patients with early-stage disease.
Breast Neoplasms* ; Breast* ; Chemotherapy, Adjuvant* ; Drug Therapy ; Drug Therapy, Combination ; Female ; Follow-Up Studies ; Hope ; Humans ; Lymph Nodes ; Prospective Studies ; Receptors, Steroid ; Taxoids